XORTX Therapeutics Inc (XRTX)
NASDAQ:XRTX
XRTX Stock Chart & Stats
$0.58
-$0.02(-1.68%)
At close: 4:00 PM EST
$0.58
-$0.02(-1.68%)
Day’s Range― - ―
52-Week Range$1.73 - $7.05
Previous CloseN/A
Volume19.17K
Average Volume (3M)3.79M
Market Cap
$3.67M
Enterprise Value-$445.91K
Total Cash (Recent Filing)$1.19M
Total Debt (Recent Filing)$51.11K
Price to Earnings (P/E)―
Beta0.49
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding1,392,444
10 Day Avg. Volume11,302,330
30 Day Avg. Volume3,791,937
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.28
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap-0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.40
Enterprise Value/Ebitda0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$2.33M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt materially reduces solvency and interest expense risk for a clinical-stage biotech. This preserves financial flexibility to pursue trials or partnerships without immediate debt servicing constraints, improving resilience through multi-quarter R&D cycles.
Moderating Cash BurnReduced cash outflows indicate management has slowed spending or improved efficiency, extending runway. A sustained trend toward lower negative FCF lessens near-term financing needs and lowers dilution risk while the company advances clinical programs.
Focused Therapeutic PipelineA concentrated R&D focus on hyperuricemia and renal indications creates clear clinical development priorities and potential for targeted partnerships or licensing. Specialization can yield durable competitive knowledge and a clearer commercialization path if trials succeed.
Bears Say
No Revenue / Ongoing LossesAbsence of revenue and persistent operating losses mean the company is not self-sustaining; continued negative earnings deepen reliance on capital markets. This structural unprofitability creates execution risk if clinical outcomes delay or fail, pressuring cash and strategy.
Equity ErosionSignificant equity decline reflects cumulative losses or dilution and weakens the balance-sheet buffer. A smaller equity base reduces capacity to absorb setbacks, increases vulnerability to funding shocks, and can constrain options for future financing or partnerships.
Dependence On External FinancingOngoing need for outside capital is a structural risk: frequent financing can dilute existing holders and may force unfavorable terms. Reliance on markets reduces strategic autonomy and raises execution risk if funding environments deteriorate during multi-year trials.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was $1.73 and its highest was $7.05 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is $3.67M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is May 14, 2026 which is in 33 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on Mar 26, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.835 by $0.585.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc pays a Quarterly dividend of $0.075 which represents an annual dividend yield of N/A. See more information on XORTX Therapeutics Inc dividends here
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,392,444 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.835. Following the earnings report the stock price went down -9.686%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Ownership Overview
Options Prices
Currently, No data available
---